Ivonescimab Beats Tislelizumab on Survival in Squamous Lung Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High
Lu S, Liu B, Luo Y, et al.
Jun 27, 2026 · Published in: Lancet (London, England)
Ivonescimab enhances survival in squamous NSCLC, offering new hope.
Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Low
Li S, Bao L, Zhou D, et al.
Jun 26, 2026 · Published in: Technology in Cancer Research & Treatment
EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.
ECIL-10 Reshapes Febrile Neutropenia Antibiotic Strategy Around Stewardship
★ Editor's Pick Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
Averbuch D, Vanbiervliet Y, Baccelli F, et al.
Jun 25, 2026 · Published in: The Lancet. Infectious Diseases
Also in Oncology
Rising resistance challenges febrile neutropenia treatment in hematologic patients.
Low-Dose Vitamin D3 With Fluoropyrimidines in Metastatic CRC: Small, Unregistered, Exploratory
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Rahman AMA, Hassan NA, Hamza MS, et al.
Jun 25, 2026 · Published in: Asian Pacific Journal of Cancer Prevention : APJCP
Vitamin D3 boosts chemotherapy response in metastatic CRC.
Sequencing Systemic Therapy in Resectable NSCLC: Equipoise Remains
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Osarogiagbon RU, Cetnar JP, Aljumaily R
Jun 23, 2026 · Published in: American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
New trials may refine lung cancer therapy timing strategies.
KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Analysis Oncology Pharmacy Confirmatory Grade: Low
Izzedine H, Perazella MA, Kuruvada KM, et al.
Jun 20, 2026 · Published in: Kidney International
Also in Nephrology
Preventing kidney damage in cancer treatment requires proactive strategies.
Pooled 5-FU Population PK Model Supports Lean Mass and Model-Informed Dosing
Analysis Pharmacokinetics / TDM Hypothesis-generating Grade: Low
Briki M, Thoueille P, Joerger M, et al.
Jun 12, 2026 · Published in: Cancer Chemotherapy and Pharmacology
Also in Oncology
Leverage lean body mass for precise 5-FU dosing!
Venetoclax-Based Regimens Reshape Chemotherapy-Free CLL Management
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Kegyes D, Muresan X, Bancos A, et al.
Jun 11, 2026 · Published in: Critical Reviews in Oncology/hematology
Venetoclax brings new promise to chronic lymphocytic leukemia management.
Daraxonrasib Shows Early Activity in RAS-Mutated Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wolpin BM, Park W, Garrido-Laguna I, et al.
May 7, 2026 · Published in: The New England Journal of Medicine
Daraxonrasib shows promise in advanced RAS-mutated pancreatic cancer.
KRAS Inhibitors May Unlock Immunotherapy in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Stanger BZ, Vonderheide RH
Apr 15, 2026 · Published in: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
KRAS inhibitors may revolutionize immunotherapy for pancreatic cancer.
Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
★ Editor's Pick Analysis Oncology Pharmacy Practice-changing Grade: High
Sinicrope FA, Ou FS, Arnold D, et al.
Mar 26, 2026 · Published in: N Engl J Med
Atezolizumab enhances survival in dMMR colon cancer.
Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Kong Y, He R, He H, et al.
Feb 25, 2026 · Published in: Rev Cardiovasc Med
Also in Cardiology
New biomarkers offer promise for early detection of chemotherapy-induced heart damage.
KRAS Inhibitors Reshape the Treatment Landscape in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Khan N, Raza U, Ali Zaidi SA, et al.
Jul 7, 2025 · Published in: Cancer Biology & Medicine
KRAS: From 'undruggable' to potential target in pancreatic cancer.
Adagrasib Shows Tumor-Agnostic Activity in Rare KRAS G12C Solid Tumors
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Bekaii-Saab TS, Yaeger R, Spira AI, et al.
Sep 1, 2023 · Published in: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Adagrasib shows promise in rare KRASG12C-mutated tumors.
Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Strickler JH, Satake H, George TJ, et al.
Jan 5, 2023 · Published in: The New England Journal of Medicine
Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.